Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 30.9% in February

Evogene Ltd. (NASDAQ:EVGN) was the target of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 188,218 shares, a decrease of 30.9% from the February 12th total of 272,348 shares. Approximately 3.8% of the company’s shares are short sold. Based on an average trading volume of 57,400 shares, the short-interest ratio is currently 3.3 days. Based on an average trading volume of 57,400 shares, the short-interest ratio is currently 3.3 days. Approximately 3.8% of the company’s shares are short sold.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in Evogene in the fourth quarter valued at $25,000. Citadel Advisors LLC increased its stake in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,387 shares during the last quarter. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Stock Performance

Evogene stock opened at $0.80 on Monday. Evogene has a 1 year low of $0.73 and a 1 year high of $2.42. The firm has a 50 day moving average price of $0.97 and a 200 day moving average price of $1.10. The company has a market cap of $4.28 million, a price-to-earnings ratio of -0.68 and a beta of 1.36.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.35). The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.28 million. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.